Kolexia
Asselah Tarik Gastro-entérologie
Asselah Tarik
Gastro-entérologie
Hôpital Beaujon
Clichy, France
350 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hépatite Hépatite C Hépatite chronique Hépatite C chronique Fibrose Hépatite B Cirrhose du foie Hépatite A Hépatite B chronique

Collaborateurs

Voir plus
Marcellin Patrick
Marcellin Patrick
Hôpital Beaujon, Clichy, France
Bourliere Marc
Bourliere Marc
Hopital Saint Joseph, Marseille, France
Boyer-Darrigrand Nathalie
Boyer-Darrigrand Nathalie
Hôpital Beaujon, Clichy, France
Pol Stanislas
Pol Stanislas
Hôpital Cochin, Paris, France

Industries

Voir plus
Gilead
47 collaboration(s)
Dernière en 2023
Abbvie
41 collaboration(s)
Dernière en 2023
GSK
10 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD): A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis Delta
Essai Clinique (Gilead)   12 septembre 2023
Hepatitis-B virus: replication cycle, targets, and antiviral approaches.
Current opinion in virology   09 septembre 2023
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
JHEP reports : innovation in hepatology   22 août 2023
BuleDelta: Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic Hepatitis B Virus (HBV)/Hepatitis D Virus (HDV) Co-infection With Severe Fibrosis Injuries, or Moderate Fibrosis Injuries Associated With Persistent Increase of ALT
Essai Clinique (Agence nationale de recherches sur le sida et les hépatites virales)   18 août 2023
What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Clinics in liver disease   14 juillet 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
The lancet. Gastroenterology & hepatology   10 juillet 2023
Hepatitis D Virus Infection.
The New England journal of medicine   07 juillet 2023
REEF-1: A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Essai Clinique (Janssen)   05 mai 2023
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Journal of hepatology   27 avril 2023
Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection.
Journal of hepatocellular carcinoma   25 avril 2023